v3.25.2
Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Collaboration revenue $ 0   $ 357   $ 0 $ 788
Stock-based compensation expense 7,770   5,878   16,556 20,353
Depreciation expense         93 219
Net loss (71,127) $ (69,296) (32,677) $ (39,553) (140,423) (72,230)
Reportable Segment            
Segment Reporting Information [Line Items]            
Collaboration revenue 0   357   0 788
Personnel-related expenses 11,913   9,843   24,943 18,110
Stock-based compensation expense 7,770   5,879   16,556 20,354
Depreciation expense 46   107   93 219
Other segment expenses 6,753   5,037   15,129 10,183
Interest income 4,940   4,811   10,372 7,144
Net loss (71,127)   (32,677)   (140,423) (72,230)
Reportable Segment | Ulixacaltamide            
Segment Reporting Information [Line Items]            
Program-specific expenses 18,385   12,045   41,898 23,184
Reportable Segment | Vormatrigine            
Segment Reporting Information [Line Items]            
Program-specific expenses 17,957   1,860   31,690 2,592
Reportable Segment | Relutrigine            
Segment Reporting Information [Line Items]            
Program-specific expenses 10,509   1,245   15,886 2,251
Reportable Segment | Elsunersen            
Segment Reporting Information [Line Items]            
Program-specific expenses 1,317   685   2,078 1,206
Reportable Segment | Other early stage assets            
Segment Reporting Information [Line Items]            
Program-specific expenses $ 1,417   $ 1,144   $ 2,522 $ 2,063